Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ESR1 | P03372 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312147 | 0.89 | KMT2A (0.76) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL11445596 | 0.87 | KMT2A (0.73) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL2242019 | 0.84 | BCL9 (0.60) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL6282777 | 0.83 | KMT2A (0.68) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL9171166 | 0.83 | KMT2A (0.68) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL370103 | 0.81 | KMT2A (0.52) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL27739371 | 0.81 | KMT2A (0.43) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL7930777 | 0.81 | KMT2A (0.66) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL361899 | 0.81 | KMT2A (0.66) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL819434 | 0.81 | KMT2A (0.66) | KMT2ASMN1; SMN2ESR1HIF1ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| WO-2017107052-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| CN-102939290-B | 2,3-dihydro-1H-indenes-1-base-2,7-diaza spiro [3.5] nonane derivatives and as the antagonist of growth hormone-releasing peptide acceptor or the purposes of inverse agonist | PFIZER INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-20140044723-A1 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY | MOCHIDA PHARM CO LTD (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8524870-B2 | Anti-platelet membrane glycoprotein VI monoclonal antibody | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130095120-A1 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8389692-B2 | Anti-platelet membrane glycoprotein VI monoclonal antibody | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| CN-102939290-A | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | PFIZER | 2013-02-20 | — | — | CN | disclosed |
| CN-101668524-B | Pyrazole derivatives as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-10-24 | — | — | CN | disclosed |
| EP-1876240-B1 | ANTI-HUMAN PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY | MOCHIDA PHARM CO LTD (JP) | 2012-08-22 | — | — | EP | disclosed |
| CN-101668524-A | Pyrazole derivatives as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2010-03-10 | — | — | CN | disclosed |
| CN-101605768-A | Sequestrant | UNIV MUENCHEN TECH (DE) | 2009-12-16 | — | — | CN | disclosed |
| US-20090092612-A1 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY | MOCHIDA PHARMACEUTICAL CO. LTD. | 2009-04-09 | — | — | US | disclosed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | disclosed |
| EP-1876240-A1 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7196214-B2 | Process for arylamine production | XEROX CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060111582-A1 | Process for arylamine production | XEROX CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| US-5206178-A | Complexing to polymer; immobilization to solid | GENETIC SYSTEMS CORPORATION (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0268296-B1 | MEMBRANE AFFINITY CONCENTRATION IMMUNOASSAY | GENETIC SYSTEMS CORPORATION (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0268296-A2 | Membrane affinity concentration immunoassay | GENETIC SYSTEMS CORPORATION (US) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111582-A1 | Process for arylamine production | AOC2, UFM1, TYR | KMT2A 969/4885SMN1; SMN2 3194/4885ESR1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.